#United States #Los Angeles #Bioelectronics #Electrome #PAINKILLER

Electrome Launches PAINKILLER™ Bioelectric Pain Management Solution

Los Angeles-based Electrome Corp has made a groundbreaking announcement: the launch of its latest bioelectric therapeutics platform, PAINKILLER™, in collaboration with BioElectronics Corp (BIEL). This novel approach to pain management leverages the synergy between Electrome's AI-driven platform and BIEL's established history in electromagnetic therapy devices.

Strategic Partnership for Pain Relief

On March 24, 2026, Electrome revealed its strategic partnership with BIEL, a pioneer in the field of electroceuticals, known for their FDA-cleared products like ActiPatch® and RecoveryRx®. The alignment of these two companies is set to amplify the national rollout of the PAINKILLER™ platform, which promises drug-free pain relief while eliminating the risks associated with addiction.

The PAINKILLER™ system is designed to provide continuous pain management without the side effects common in traditional medications. Built around wearable Pulsed Electromagnetic Field (PEMF) technology, this innovative platform personalizes treatment protocols through AI analysis, aligning perfectly with contemporary value-based care models.

Bridging Technology with Clinical Needs

Electrome's entry into the pain management arena reflects a significant step towards addressing the unmet needs in postoperative and chronic pain management. The partnership will allow for early deployments within the U.S. Department of Veterans Affairs (VA) and aims to expand into approximately 3,700 retail pharmacies across the country by the third quarter of 2026.

The integration of BAEL's FDA-cleared devices allows Electrome to capitalize on decades of clinical data, while also establishing a robust manufacturing and regulatory framework. This collaboration provides the groundwork necessary for entering the high-value therapeutic market while addressing critical pain management issues.

The Science Behind PAINKILLER™

What differentiates Electrome's PAINKILLER™ from other pain management solutions is its commitment to non-pharmacologic therapies. Clinical studies of BIEL's existing products, like RecoveryRx® and ActiPatch®, have shown significant reductions in pain levels and inflammation, decreased reliance on opioids, and positive outcomes regarding functional recovery and mobility. The safety profile of these therapies, devoid of systemic side effects, positions them as valuable tools within multimodal pain management strategies.

Leadership Vision

Management at Electrome expresses a strong commitment to advancing bioelectronic medicine. CEO Ken Mayer emphasizes the importance of their partnership with BIEL in translating bioelectric science into mainstream medicine, aiming to improve patient care while reducing dependence on narcotics. Dr. Nev Zubcevik, CMO and Co-Founder of Electrome, highlights the platform's potential to provide data-driven solutions that integrate seamlessly with common clinical workflows.

As bioelectric therapies continue to gain momentum, this collaboration illustrates a significant movement towards broader acceptance and use of electroceutical technologies in clinical and consumer markets alike. CEO Kelly Whelan of BioElectronics stated that this initiative is a crucial step in fostering the widespread adoption of bioelectric therapies.

About Electrome Corp and BioElectronics

Electrome Corp is at the forefront of bioelectric therapeutics, focused on translating scientific breakthroughs into effective, non-invasive treatments across various health issues, including pain and infection management. Meanwhile, BioElectronics Corporation remains a leader in the electroceutical sector, boasting a portfolio of FDA-cleared devices and a successful global distribution network.

The launch of the PAINKILLER™ platform marks a pivotal advancement in pain management strategies, opening doors to innovative, accessible solutions that prioritize patient well-being without the adverse effects associated with traditional pharmacological treatments.